Literature DB >> 17981227

The immunology of hepatitis B.

John M Vierling1.   

Abstract

The hepatitis B virus (HBV) is an enveloped, hepatotrophic, oncogenic hepadnavirus that is noncytopathic for hepatocytes. HBV infection results in a variety of outcomes that are determined by the quality, quantity, and kinetics of the host innate and adaptive immune responses. Whether HBV infection is cleared or persists as a progressive or nonprogressive liver disease is determined by both viral and host factors. Replicative intermediates can persist in the liver under immunologic control after resolution of acute or chronic hepatitis B, conferring a risk for reactivation following a course of immunosuppression or chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981227     DOI: 10.1016/j.cld.2007.08.001

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  24 in total

1.  Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.

Authors:  Jorge Méndez-Navarro; Kathleen E Corey; Hui Zheng; Lydia L Barlow; Jae Young Jang; Wenyu Lin; Hong Zhao; Run-Xuan Shao; Steven L McAfee; Raymond T Chung
Journal:  Liver Int       Date:  2010-08-25       Impact factor: 5.828

Review 2.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

Review 3.  Hepatitis B virus management to prevent reactivation after chemotherapy: a review.

Authors:  Jessica P Hwang; John M Vierling; Andrew D Zelenetz; Susan C Lackey; Rohit Loomba
Journal:  Support Care Cancer       Date:  2012-08-30       Impact factor: 3.603

Review 4.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

Review 5.  Acute exacerbation of chronic hepatitis B: the dilemma of differentiation from acute viral hepatitis B.

Authors:  Pankaj Puri
Journal:  J Clin Exp Hepatol       Date:  2013-10-17

Review 6.  Designing immune therapy for chronic hepatitis B.

Authors:  Sheikh Mohammad Fazle Akbar; Mamun Al-Mahtab; Yoichi Hiasa
Journal:  J Clin Exp Hepatol       Date:  2014-06-26

7.  Modeling the adaptive immune response in HBV infection.

Authors:  Noura Yousfi; Khalid Hattaf; Abdessamad Tridane
Journal:  J Math Biol       Date:  2011-01-14       Impact factor: 2.259

8.  Involvement of Th17 and Th1 effector responses in patients with Hepatitis B.

Authors:  Yufu Ye; Xiaojun Xie; Jiwei Yu; Lin Zhou; Haiyang Xie; Guoping Jiang; Xiaobo Yu; Wenjin Zhang; Jian Wu; Shusen Zheng
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

9.  Implication of Th17 and Th1 cells in patients with chronic active hepatitis B.

Authors:  Jian Ge; Kai Wang; Qing-Hua Meng; Zhao-Xia Qi; Fan-Li Meng; Yu-Chen Fan
Journal:  J Clin Immunol       Date:  2009-09-10       Impact factor: 8.317

10.  The effect of human immunodeficiency virus on hepatitis B virus serologic status in co-infected adults.

Authors:  Michael L Landrum; Ann M Fieberg; Helen M Chun; Nancy F Crum-Cianflone; Vincent C Marconi; Amy C Weintrob; Anuradha Ganesan; Robert V Barthel; Glenn Wortmann; Brian K Agan
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.